Christopher J. Logothetis
YOU?
Author Swipe
View article: KDM4A promotes NEPC progression through regulation of MYC expression
KDM4A promotes NEPC progression through regulation of MYC expression Open
Neuroendocrine prostate cancer (NEPC) is a highly aggressive and lethal subtype of prostate cancer (PCa) that often emerges in response to androgen receptor pathway inhibitors (ARPIs), which are widely used in treating metastatic castratio…
View article: Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer
Biomarkers to optimize PSMA-targeted radioligand therapy for metastatic castration-resistant prostate cancer Open
Although the recently approved prostate-specific membrane antigen (PSMA)-targeted radioligand therapy (RLT) [ 177 Lu]Lu-PSMA-617 has improved outcomes for patients with metastatic castration-resistant prostate cancer (mCRPC), not all patie…
View article: PKA-driven SPP1 activation as a novel mechanism connecting the bone microenvironment to prostate cancer progression
PKA-driven SPP1 activation as a novel mechanism connecting the bone microenvironment to prostate cancer progression Open
Prostate cancer (PCa) bone metastasis (BM) poses a significant clinical challenge due to the heterogeneity of treatment responses and patient outcomes. In this study, we examined the role of Protein Kinase A (PKA) signaling in modulating t…
View article: Figure S14 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Figure S14 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure S14. Tumor subclone changes in longitudinal ctDNA samples: P217, P220, P229, P244, P251, and P259
View article: Figure S23 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Figure S23 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure S23. Correlation between ctDNA fraction changes and EDI during chemotherapy
View article: Supplementary Figure Legends from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Supplementary Figure Legends from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure Legends
View article: Figure S9 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Figure S9 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure S9. Tumor subclone changes in longitudinal ctDNA samples: P27, P35, P149, P263, P77, and P151
View article: Figure S12 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Figure S12 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure S12. Tumor subclone changes in longitudinal ctDNA samples: P147, P157, P162, P165, P166, and P172
View article: Table S7 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Table S7 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Cox proportional hazards model of genomic aberrations and progression free survival of chemotherapy
View article: Figure S7 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Figure S7 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure S7. Prognostic significance of clinical features and genomic aberrations at baseline timepoints, before therapies
View article: Figure S4 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Figure S4 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure S4. Genomic alterations in 4 patients with African American ancestry
View article: Figure S24 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Figure S24 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure S24. Genomic response to Radium-223 therapy
View article: Figure S6 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Figure S6 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure S6. Mutation signature and CNV signature changes in relation to treatments
View article: Figure S21 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Figure S21 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure S21. Estimated AR copy number comparison between pre-treatment (BL) and PD for chemotherapy
View article: Figure S22 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Figure S22 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure S22. Survival analysis of identified genomic alterations that related to chemotherapy resistance or shorter PFS of chemotherapy in cBioPortal
View article: Table S6 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Table S6 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Mutational CCF changes during Chemotherapy
View article: Figure S15 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Figure S15 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure S15. Tumor subclone changes in longitudinal ctDNA samples: P262, P270, P344, P354, P364, and P379
View article: Figure S1 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Figure S1 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure S1. cfDNA molecular features
View article: Figure S5 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Figure S5 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure S5. Focal tandem duplication patterns identified in patients with CDK12 mutations
View article: Table S4 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Table S4 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Mutational CCF changes during ASI
View article: Figure S17 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Figure S17 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure S17. Clonal substructure, evolutionary dynamics, and genomic features in relation to clinical parameters
View article: Figure S13 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Figure S13 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure S13. Tumor subclone changes in longitudinal ctDNA samples: P182, P190, P196, P198, P203, and P204
View article: Figure S19 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Figure S19 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure S19. Survival analysis of genomic alterations that related to ASI resistance or shorter PFS of ASI in cBioPortal
View article: Figure S20 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Figure S20 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure S20. Correlation between ctDNA fraction changes and EDI during ASI
View article: Figure S16 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Figure S16 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure S16. Clinical significance of clonal diversity, evolutionary dynamic index, and genomic complexity
View article: Figure S8 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Figure S8 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure S8. CNV profiles of patients with MCM7 alterations
View article: Figure S3 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Figure S3 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure S3. Significant copy number variations in the ctDNA samples
View article: Table S3 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Table S3 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Shannon diversity index of the ctDNA samples
View article: Table S2 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Table S2 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Cox proportional hazards model of the genomic aberrations and overall survival
View article: Figure S2 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy
Figure S2 from Longitudinal Profiling of Circulating Tumor DNA Reveals the Evolutionary Dynamics of Metastatic Prostate Cancer during Serial Therapy Open
Supplementary Figure S2. Landscape of genomic aberrations in longitudinal plasma samples